Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.

Issue 11, 2018
Previous Article Next Article

Towards identifying potent new hits for glioblastoma

Author affiliations


Glioblastoma is a devastating disease of the brain and is the most common malignant primary brain tumour in adults. The prognosis for patients is very poor with median time of survival after diagnosis measured in months, due in part to the tumours being highly aggressive and often resistant to chemotherapies. Alongside the ongoing research to identify key factors involved in tumour progression in glioblastoma, medicinal chemistry approaches must also be used in order to rapidly establish new and better treatments for brain tumour patients. Using a computational similarity search of the ZINC database, alongside traditional analogue design by medicinal chemistry intuition to improve the breadth of chemical space under consideration, six new hit compounds (14, 16, 18, 19, 20 and 22) were identified possessing low micromolar activity against both established cell lines (U87MG and U251MG) and patient-derived cell cultures (IN1472, IN1528 and IN1760). Each of these scaffolds provides a new platform for future development of a new therapy in this area, with particular promise shown against glioblastoma subtypes that are resistant to conventional chemotherapeutic agents.

Graphical abstract: Towards identifying potent new hits for glioblastoma

Back to tab navigation

Supplementary files

Article information

31 Aug 2018
01 Oct 2018
First published
02 Oct 2018

Med. Chem. Commun., 2018,9, 1850-1861
Article type
Research Article

Towards identifying potent new hits for glioblastoma

C. Sherer, S. Prabhu, D. Adams, J. Hayes, F. Rowther, I. Tolaymat, T. Warr and T. J. Snape, Med. Chem. Commun., 2018, 9, 1850
DOI: 10.1039/C8MD00436F

Search articles by author